公开(公告)号：US10683294B2

公开(公告)日：2020-06-16

申请号：US15991747

申请日：2018-05-29

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen Fan ,  Christopher W. Lange ,  Rebecca M. Lui ,  Viengkham Malathong ,  Venkat Reddy Mali ,  Sreenivas Punna ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D487/04 ,  A61P37/02

Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

公开(公告)号：US20160296508A1

公开(公告)日：2016-10-13

申请号：US15074965

申请日：2016-03-18

Applicant: ChemoCentryx, Inc.

Inventor： Daniel Dairaghi ,  Dean R. Dragoli ,  Jarek Kalisiak ,  Christopher W. Lange ,  Manmohan Reddy Leleti ,  Yandong Li ,  Rebecca M. Lui ,  Venkat Reddy Mali ,  Viengkham Malathong ,  Jay P. Powers ,  Hiroko Tanaka ,  Joanne Tan ,  Matthew J. Walters ,  Ju Yang ,  Penglie Zhang

IPC: A61K31/47 ,  A61K31/4709

CPC classification number: A61K31/47 ,  A61K31/4709 ,  C07D215/48 ,  C07D405/04 ,  C07D405/14

Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

公开(公告)号：US20140154179A1

公开(公告)日：2014-06-05

申请号：US14091641

申请日：2013-11-27

Applicant: ChemoCentryx, Inc.

Inventor： Junfa Fan ,  Antoni Krasinski ,  Christopher W. Lange ,  Rebecca M. Lui ,  Jeffrey P. McMahon ,  Jay P. Powers ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D487/04 ,  A61K49/10 ,  A61K51/04

CPC classification number: C07D487/04 ,  A61K51/0459 ,  G01N33/57492 ,  G01N2333/7158

Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

Abstract translation: 提供具有式I化合物或其药学上可接受的盐，水合物或N-氧化物，并且可用于结合CXCR7，并且治疗至少部分依赖于CXCR7活性的疾病。 因此，本发明还提供含有一种或多种上述化合物与药学上可接受的赋形剂混合的组合物。

公开(公告)号：US20130237514A1

公开(公告)日：2013-09-12

申请号：US13645921

申请日：2012-10-05

Applicant: CHEMOCENTRYX, INC

Inventor： Trevor T. Charvat ,  Hiufung Chu ,  Antoni Krasinski ,  Christopher W. Lange ,  Manmohan Reddy Leleti ,  Jay P. Powers ,  Sreenivas Punna ,  Timothy J. Sullivan ,  Solomon Ungashe

IPC: C07D207/277 ,  C07D405/04 ,  C07D491/052 ,  C07D413/06 ,  C07D209/52 ,  C07D209/46 ,  C07D401/04 ,  C07D491/048 ,  C07D403/06

CPC classification number: C07D207/277 ,  C07D207/416 ,  C07D209/46 ,  C07D209/52 ,  C07D401/04 ,  C07D401/06 ,  C07D403/06 ,  C07D405/04 ,  C07D413/06 ,  C07D491/048 ,  C07D491/052 ,  C07D493/04

Abstract: Pyrrolidinone carboxamide compounds are provided that are useful for inhibiting the binding of ligands to the ChemR23 receptor.

Abstract translation: 提供吡咯烷酮甲酰胺化合物，其可用于抑制配体与ChemR23受体的结合。

公开(公告)号：US11884654B2

公开(公告)日：2024-01-30

申请号：US17470464

申请日：2021-09-09

Applicant: CHEMOCENTRYX, INC.

Inventor： Trevor T. Charvat ,  Junfa Fan ,  Christopher W. Lange ,  Manmohan Reddy Leleti ,  Yandong Li ,  Venkat Reddy Mali ,  Jeffrey P. McMahon ,  Jay Powers ,  Sreenivas Punna ,  Ju Yang

IPC: A01N43/00 ,  A61K31/00 ,  C07D413/06 ,  C07D401/04 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D417/04 ,  C07D211/56 ,  C07D295/135 ,  C07D211/62 ,  C07D211/26 ,  C07D211/70 ,  C07D241/04 ,  C07D207/16 ,  C07D211/34 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5377

CPC classification number: C07D413/06 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5377 ,  C07D207/16 ,  C07D211/26 ,  C07D211/34 ,  C07D211/56 ,  C07D211/62 ,  C07D211/70 ,  C07D241/04 ,  C07D295/135 ,  C07D401/04 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D417/04

Abstract: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

公开(公告)号：US11834452B2

公开(公告)日：2023-12-05

申请号：US17331750

申请日：2021-05-27

Applicant: CHEMOCENTRYX, INC.

Inventor： Junfa Fan ,  Antoni Krasinski ,  Christopher W. Lange ,  Rebecca M. Lui ,  Jeffrey P. McMahon ,  Jay P. Powers ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D487/04 ,  A61K51/04 ,  G01N33/574

CPC classification number: C07D487/04 ,  A61K51/0459 ,  G01N33/57492 ,  G01N2333/7158

Abstract: Compounds having formula I,




or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

公开(公告)号：US11478460B2

公开(公告)日：2022-10-25

申请号：US17033124

申请日：2020-09-25

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen Fan ,  Christopher W. Lange ,  Viengkham Malathong ,  Venkat Reddy Mali ,  Sreenivas Punna ,  Hiroko Tanaka ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D471/04 ,  A61K31/437 ,  A61P37/00 ,  A61P35/00 ,  A61P9/00 ,  A61K45/06

Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

公开(公告)号：US11384079B2

公开(公告)日：2022-07-12

申请号：US16723433

申请日：2019-12-20

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen Fan ,  Christopher W. Lange ,  Rebecca M. Lui ,  Viengkham Malathong ,  Venkat Reddy Mali ,  Sreenivas Punna ,  Rajinder Singh ,  Hiroko Tanaka ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D471/04 ,  A61P37/02 ,  C07D519/00

Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

公开(公告)号：US11059825B2

公开(公告)日：2021-07-13

申请号：US16379599

申请日：2019-04-09

Applicant: CHEMOCENTRYX, INC.

Inventor： Junfa Fan ,  Antoni Krasinski ,  Christopher W. Lange ,  Rebecca M. Lui ,  Jeffrey P. McMahon ,  Jay P. Powers ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D487/04 ,  A61K51/04 ,  G01N33/574

Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

公开(公告)号：US10117865B2

公开(公告)日：2018-11-06

申请号：US15709012

申请日：2017-09-19

Applicant: CHEMOCENTRYX, INC.

Inventor： Daniel Dairaghi ,  Dean R. Dragoli ,  Jaroslaw Kalisiak ,  Christopher W. Lange ,  Manmohan Reddy Leleti ,  Yandong Li ,  Rebecca M. Lui ,  Venkat Reddy Mali ,  Viengkham Malathong ,  Jay P. Powers ,  Hiroko Tanaka ,  Joanne Tan ,  Matthew J. Walters ,  Ju Yang ,  Penglie Zhang

IPC: A61K31/47 ,  A61K31/4709 ,  C07D215/48 ,  C07D405/04 ,  C07D405/10 ,  C07D405/14

Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6: